Q1FY21 results: Bliss GVS Pharma net profit declines by 50 per cent YoY to Rs 16.65 crore
Bliss GVS Pharma Limited announced its Q1FY21 results on Aug 20, 2020. The company reported consolidated net sales of Rs 129.55 crore in Q1FY21, which declined by 38.76 per cent YoY from Rs 211.53 crore in Q1FY20.
The company posted EBITDA of Rs 19.48 crore in Q1FY21 that decreased by 60.21 per cent YoY. For Q1FY20, it had posted EBITDA of Rs 48.96 crore. EBITDA margin as of Q1FY21 was at 15.04 per cent that declined by 8.11 per cent YoY. EBITDA margin for Q1FY20 was 23.15 per cent.
The consolidated net profit in Q1FY21 came in at Rs 16.65 crore, which declined by 50.09 per cent, as compared to Q1FY20, when it reported a profit of Rs 33.36 crore. The net profit margin in Q1FY21 came in at 12.85 per cent, which declined by 2.92 per cent YoY. The net profit margin for Q1FY20 was 15.77 per cent.
On Friday, share price of the company at 11.27am was trading at Rs 128, down by 3.47 by per cent.
|
Particulars
|
Q1FY21 (Rs in cr)
|
Q1FY20 (Rs in cr)
|
Per cent change
|
|
Net Profit
|
16.65
|
33.36
|
-50.09
|
|
Net Revenue
|
129.55
|
211.53
|
-38.76
|
|
Operating Profit
|
19.48
|
48.96
|
-60.21
|
|
EBITDAM%
|
15.04
|
23.15
|
-8.11
|
|
PATM%
|
12.85
|
15.77
|
-2.92
|